44.25
-1.84%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sichuan Kelun Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 002422.SZ. It has been listed since 3 June 2010. In the fiscal year to 31 December 2025, it reported revenue of CN¥18.51bn and net income of CN¥1.70bn. At that date it held total assets of CN¥39.83bn and shareholders' equity of CN¥24.22bn.
Sichuan Kelun Pharmaceutical Co., Ltd. engages in research, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Chengdu, Sichuan. The company went IPO on 2010-06-03. The firm operates its businesses through manufacture and distribution of injections, booster injections, lyophilized power injections, tablets, capsules, granules, oral liquids, dialysis fluids and other form of pharmaceuticals, bulk pharmaceutical chemicals, pharmaceutical packing materials, as well as medical equipment. The firm's injection products include general injections and therapeutic injections, such as glucose injections, sodium chloride injections, glucose and sodium chloride injections, ofloxacin injections, metronidazole injections and norfloxacin injections, among others. Through its subsidiaries, it also engages in the manufacture of rubber and plastic products. The firm distributes its products within domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 3 Jun 2010
- Employees
- 18,422
- Website
- kelun.com ↗
Leadership
Pay as last reported
- Mr. Gexin LiuChairman of the Board, since 1996CN¥5.6m
- Mr. Degui LaiChief Financial Officer, Deputy General ManagerCN¥3.0m
- Mr. Sichuan LiuGeneral Manager, Director, since 2009CN¥4.8m
- Mr. Hao FengDeputy General Manager, Secretary of the BoardCN¥3.0m
- Ms. Yihong LiaoDeputy General ManagerCN¥2.2m
- Mr. Hongbo TanDeputy General ManagerCN¥3.0m
- Mr. Juncai WeiDeputy General ManagerCN¥3.5m
- Mr. Zhonghua WuDeputy General ManagerCN¥3.0m
- Mr. Junyou GeDirector, since 2007CN¥4.1m
- Mr. Guosheng HeDirectorCN¥138,000
- Mr. Guangji WangDirectorCN¥138,000
- Mr. Xianxiang ZhouDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 88
- Environment
- 99
- Social
- 99
- Governance
- 66
- Direct emissions (scope 1)
- 2,361,763.17 t
- Energy emissions (scope 2)
- 483,786.08 t
- Women in the workforce
- 44.72%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sichuan Kelun Pharmaceutical employs 18,422 full-time employees in Chengdu, China.
- The company manufactures diverse pharmaceutical products including injections and tablets.
- Sichuan Kelun operates in the Health Care sector with a strong domestic presence.
Weaknesses
- The company's business is limited to pharmaceutical manufacturing and distribution in China.
- Sichuan Kelun relies on domestic market sales without significant overseas expansion.
- The firm's product range focuses on basic pharmaceuticals without advanced innovation.
Opportunities
- Expanding into overseas markets for pharmaceutical products offers growth potential.
- Increasing demand for health care services in China supports pharmaceutical sales.
- Sichuan Kelun can leverage its 18,422 employees for further R&D initiatives.
Threats
- Competition from other Chinese pharmaceutical companies in the domestic market.
- Regulatory changes in China's Health Care sector could impact operations.
- Overreliance on domestic market sales exposes the company to local economic risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.